

April 12, 2013 Maputo, Mozambique Overall Chair: D Havlir

Meeting objectives:

- To assess progress, and identify challenges and opportunities for catalyzing the implementation and scale-up of collaborative TB/HIV activities over the next five years
- To define the strategic direction and terms of Reference of the TB/HIV Working Group and infection control subgroup

Eliminating TB deaths among people living with HIV		
08:30-09:00	Introduction and overview	Diane Havlir
09:00-09:20	What is new on combination TB prevention?	Lisa Nelson
09:20-09:25	Commentary	Jonathan Golub
09:25-10:00	General Discussion: directions on ART for TB prevention, IPT & ART/IPT efficacy and durability, the need for TST/IGRA, rifapentine versus IPT, combined delivery of IPT with CPT, infection control and TB transmission, key populations, monitoring the impact, remaining research priorities.	
10:00-10:20	What is new on HIV associated TB diagnosis?	Haileyesus Getahun
10:20-10:25	Commentary	Helen Ayles
10:25-11:00	General Discussion: directions on strategies, results and implications of Xpert MTB/RIF roll-out including its use as a screening tool, progress towards POC diagnosis, potential combination of tools, e.g. symptom screening, Urine LAM, Xpert MTB/RIF, remaining research priorities. Coffee/tea	
11.00-11.20	Collee/led	
11:20-11:40	What's new in TB/HIV treatment?	Diane Havlir
11:40-11:45	Commentary	Jefter Mxotshwa
11:45-12:30	General Discussion: directions on early ART, co-management of HIV & TB (incl. MDR), Drug-drug interactions and key populations - children and nursing mothers living with HIV, drugusers, treatment monitoring and monitoring and evaluation.	
12:30-13:30	Lunch	
Terms of Reference of the TB/HIV Working Group (Closed meeting for CG members only)		
13:30-13.45	Outline of Terms of Reference of the TB/HIV Working Group: Mission, functions, focus and composition of membership.	
13:45-14:45	Discussion	
14:45-15:00	Conclusion, summary of next steps and wrap-up	